Neurocrine Biosciences revenue and financials

NBIX · NASDAQ · USD

$145.51+0.90%+$1.30

Close · October 6, 2026

In the fiscal year ended December 2025, Neurocrine Biosciences reported revenue of $2.86B (+21.45% year over year). Net income was $478.6M, a net margin of 16.7%.

Annual revenue · 2025: $2.86B

$15M2016
$161.63M2017
$451.2M2018
$788.1M2019
$1.05B2020
$1.13B2021
$1.49B2022
$1.89B2023
$2.36B2024
$2.86B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +21.45%; 2025 vs 2024
Net income growth: +40.23%; 2025 vs 2024
Net margin: 16.7%; 2024: 14.5%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	5,359	4,906	4,632	4,266	3,890	3,688	3,719	3,535	3,305	3,472	3,251	2,848
Current assets	1,638	2,436	2,523	2,158	1,749	1,638	1,725	1,877	1,670	1,799	1,607	1,650
Cash and equivalents	332	267	713	340	264	194	233	349	140	396	251	294
Short-term investments	57.4	1,050	767	775	712	749	843	879	899	814	781	801
Receivables	887	768	687	728	596	516	479	481	468	451	439	418
Inventory	104	64.5	69.0	69.3	56.9	59.1	57.4	45.8	42.5	37.2	38.3	28.8
Net property, plant and equipment	539	538	545	566	584	589	592	337	343	346	347	150
Goodwill	501	—	—	—	—	—	—	6.1	—	—	5.8	—
Other intangible assets	2,226	—	—	35.7	37.2	36.4	—	34.5	33.5	34.3	35.5	34.9
Long-term investments	239	1,477	1,184	1,117	961	910	864	771	781	864	849	588
Current liabilities	875	832	743	638	546	523	508	430	399	713	655	692
Accounts payable	142	120	105	120	105	110	99.9	95.7	107	87.3	133	93.8
Total debt	402	406	415	428	439	—	—	—	—	—	—	—
Total liabilities	1,666	1,499	1,378	1,262	1,196	1,152	1,129	816	796	1,086	1,019	846
Total equity (incl. minority)	3,694	3,407	3,253	3,004	2,694	2,536	2,590	2,719	2,509	2,386	2,232	2,002
Retained earnings	724	590	448	294	84.5	-5.3	29.2	81.1	-48.7	-114	-157	-305